[MORPHOFUNCTIONAL STATE OF BLOOD CELLS AFTER CHRONIC EXPOSURE OF THE PROTEIN KINASES INHIBITOR MALEIMIDE DERIVATIVE]

Area of Science:

• Pharmacology
• Hematology
• Oncology

Context:

• Protein kinase inhibitors are crucial in cancer therapy.
• MI-1 is a novel maleimide derivative with demonstrated antineoplastic activity.
• Understanding the safety profile of potential anticancer drugs on blood parameters is essential.

Purpose:

• To evaluate the effects of the protein kinase inhibitor MI-1 on the blood cell parameters of rats following chronic administration.
• To assess the safety of MI-1 concerning hematopoiesis in healthy rats.

Summary:

• Chronic administration of MI-1 at doses of 0.027 and 2.7 mg/kg for 20 and 26 weeks did not alter red blood cell parameters (hemoglobin, count, MCV, MCH, MCHC, hematocrit, reticulocytes) in healthy rats.
• MI-1 did not affect the total leukocyte count or differential counts (granulocytes, lymphocytes, monocytes).
• Platelet counts remained unchanged, indicating no inhibition of thrombocytopoiesis.

Impact:

• The findings suggest that MI-1 does not negatively impact hematopoiesis.
• This supports the potential use of MI-1 as an anticancer drug with a favorable safety profile regarding blood cell parameters.
• Further research can explore its efficacy and safety in clinical settings.